EUCTR2018-001878-21-GB进行中（未招募）1 期
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 179
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Aged 18 to 55 years from the day prior to signing the consent form.
- •2. In good health with no history of major medical conditions that will interfere with subject safety, as defined by medical history, physical examination, and routine laboratory tests and determined by the Investigator at screening evaluation.
- •3. Subjects will have a documented medical history either prior to entering the study and/or following medical history review with the study physician at screening.
- •4. A total body weight = 50 kg and Body Mass Index (BMI) = 18 kg/m2 and = 30kg/m2.
- •5. • Female subjects must have a negative pregnancy test at screening and prior to viral challenge.
- •Female subjects of childbearing potential must use one form of highly effective contraception. Hormonal methods must be in place from at least 2 weeks prior to quarantine. The contraception use must continue until 90 days after the date of Viral Challenge/last dosing with IMP (whichever occurs last). Highly effective contraception as below:
- •Established (a minimum of 2 weeks prior to admission) use of hormonal methods of contraception below.
- •Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- •Oral, Intravaginal, Transdermal.
- •Progestogen-only hormonal contraception associated with inhibition of ovulation:
- •Oral, injectable, implantable 2
- •Note: when hormonal methods of contraception are used, male partners are required to use a condom with a spermicide.
- •Intrauterine device (IUD) , Intrauterine hormone-releasing system (IUS) , Bilateral tubal ligation, Male sterilisation (with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate) where the vasectomised male is the sole partner for that woman.
- •True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.
- •Female subjects who are no longer of child bearing potential.
- •Post-menopausal females as defined in the protocol as having a history of amenorrhea for at least 2 years, otherwise they should have documented status as being surgically sterile or post hysterectomy.
- •Male subjects must agree to the contraceptive requirements below at entry to quarantine and continuing until 90 days after the date of Viral challenge / last dosing with IMP (whichever occurs last).
- •Use a condom with a spermicide to prevent pregnancy.
- •Male sterilisation with the appropriate post vasectomy documentation. This applies only to males participating in the study.
- •In addition, for female partners of child bearing potential, that partner must use another form of contraception such as one of the highly effective methods mentioned above for female subjects.
- •True abstinence as defined in the protocol.
- •In addition to the contraceptive requirements above, male subjects must agree not to donate sperm following discharge from quarantine until 90 days after the date of Viral Challenge/last dosing with IMP (whichever occurs last).
- •6. An informed consent document signed and dated by the subject and the Investigator.
- •7. Sero-suitable to the challenge virus.
- •The serology result obtained suggests that the subject is sensitive to RSV infection, i.e. they are likely to be infected following inoculation with the challenge virus.
- •8. Subjects who have experienced no more than one mild episode of wheeze (mild is def
排除标准
- •1. Subjects who have smoked = 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years]).
- •Of those subjects that have smoked <10 pack years at any time, a subject will be excluded if, in the last month (i.e. 30 days) prior to admission, they have used tobacco in any form (e.g. smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch and electronic cigarettes).
- •2. Females who:
- •a) Are breastfeeding, or
- •b) Have been pregnant within 6 months prior to the study, or
- •c) Have a positive pregnancy test at any point during screening or prior to Viral Challenge/first dosing with IMP (whichever occurs first).
- •3. • Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunesuppression), metabolic, urological, renal, neurological, or psychiatric disease (including subjects with a history of depression and/or anxiety with associated severe psychiatric comorbidities, for example psychosis; subjects with a history of depression of any severity within the last 2 years should only be included if the PHQ-9 score is less than or equal to 4)
- •And/or other major disease that, in the opinion of the Investigator, may interfere with a subject completing the study and necessary investigations.
- •The following conditions apply:
- •Subjects with clinically mild atopic eczema/atopic dermatitis and clinically mild psoriasis may be included at the Investigator's discretion (e.g., if small amounts of regular topical steroids are used, no eczema in cubital fossa; moderate to large amounts of daily dermal corticosteroids is an exclusion).
- •Subjects with a physician diagnosed underactive thyroid who have been controlled on treatment for at least 6 months with evidence of a normal thyroid function test (TFT) can be included at the discretion of the PI.
- •Rhinitis (including hay fever) which is clinically active or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of admission to quarantine will be excluded. Subjects with a history of currently inactive rhinitis (within the last 30 days) or mild rhinitis may be included at the PI’s discretion.
- •Any concurrent serious illness including history of malignancy that may interfere with the aims of the study or a subject completing the study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of recurrence is also an exclusion.
- •Subjects reporting physician diagnosed migraine can be included as long as there are not associated neurological symptoms such as hemiplegia or visual loss. Cluster headache/migraine or prophylactic treatment for migraine is an exclusion.
- •4. A forced expiratory volume in 1 second (FEV1) < 80%.
- •5. Subjects with any history of physician diagnosed and/or objective test confirmed asthma, COPD, pulmonary hypertension, or chronic lung condition of any aetiology.
- •6. Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.
- •7. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or
研究者
相似试验
进行中（未招募）
1 期
A clinical trial of RV521 in healthy volunteersMedDRA version: 20.0 Level: PT Classification code 10061603 Term: Respiratory syncytial virus infection System Organ Class: 10021881 - Infections and infestationsRespiratory Syncytial Virus InfectionEUCTR2017-001282-24-GBReViral Ltd66
进行中（未招募）
1 期
A study to compare ALS-008176 with a placebo to evaluate the safety, what the body does to the drug and how the drug effects the action of respiratory syncytial viral infection in healthy volunteers. The study uses multiple doses which are given orally.Respiratory Syncytial Virus (RSV) infectionMedDRA version: 16.1Level: HLTClassification code 10038717Term: Respiratory syncytial viral infectionsSystem Organ Class: 100000004862EUCTR2013-004036-30-GBAlios BioPharma
进行中（未招募）
1 期
Respiratory Syncytial Virus challenge study of BTA-C585 in healthy volunteers.Respiratory Syncytial VirusEUCTR2015-004296-77-GBBiota Pharma Europe Limited60
进行中（未招募）
1 期
A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI 0382 is well tolerated.MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2018-000019-26-GBMedImmune Limited, a wholly owned subsidiary of AstraZeneca41
进行中（未招募）
1 期
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaModerate-to-Severe Uncontrolled AsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-003338-35-SKAstraZeneca AB666